{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-23-000037","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.071832+00:00","generated_at":"2026-06-20T17:41:16.391525+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Selecta licenses Xork IgG protease to Astellas for up to $340M plus royalties for Pompe disease","bullets":["Licenses Xork to Astellas for $10M upfront, up to $340M in milestones plus royalties on sales for Pompe disease.","Phase 3 DISSOLVE I & II topline data for SEL-212 in chronic refractory gout expected in Q1 2023.","Selected IL-2 development candidate to combine with ImmTOR for autoimmune diseases; IND-enabling studies planned in 2023.","Initiated Phase 1/2 ReiMMAgine trial of SEL-302 (AAV gene therapy + ImmTOR) for methylmalonic acidemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-23-000037","json":"https://secwatch.observer/filing/0001453687-23-000037.json","markdown":"https://secwatch.observer/filing/0001453687-23-000037.md","text":"https://secwatch.observer/filing/0001453687-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/0001453687-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/selb-20230104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:41:16.391525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e42392805e","claim":"Göran A. Ando retired as Director at Cartesian Therapeutics, Inc..","evidence_excerpt":"On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”), notified the Company that he is retiring from the Company’s Board effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/0001453687-23-000037-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}